Advanced search

802 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Alcon Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Arthur J. Gallagher & Co. Acquires Acumen Advisors, Inc.	05-13	PR
Arthur J. Gallagher & Co. acquired Acumen Advisors, Inc.	05-12	CI
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024	05-10	GL
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024	05-10	AQ
CVS Health : 2024 Annual Report	05-02	PU
Canadian Natural Resources Limited Announces 2024 First Quarter Results	05-02	NE
Transcript : Hingham Institution for Savings - Shareholder/Analyst Call	04-25
The Taiwan Fund, Inc. Announces the Results of the Annual Stockholders Meeting	04-24	PR
Pembina Pipeline : About Pembina Pipeline Corporation - Form 6-K	03-28	PU
Kirby : 2024 Proxy Statement	03-11	PU
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	03-10	BU
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	03-10	AQ
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	03-10	GL
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	03-04	GL
Canadian Natural Resources Limited Announces 2023 Fourth Quarter and Year End Results	02-29	NE
Kirby McInerney LLP Reminds Hut 8 Corp. (HUT) Investors of Class Action Filing and Encourages Investors to Contact the Firm	02-23	BU
OceanaGold Reports Mineral Reserves and Resources for the Year Ended 2023	02-21	AQ
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Hut 8 Corp. (HUT) Investors	02-08	BU
Kirby Corporation Announces 2023 Fourth Quarter and Full Year Results	02-01	GL
Kirby Corporation Announces 2023 Fourth Quarter and Full Year Results	02-01	AQ
Kirby Corporation Announces Management Changes, Effective April 26, 2024	02-01	CI
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Hut 8 Corp. (HUT)	01-23	BU
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer	01-08	BU
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Microvast Holdings, Inc. (MVST) Investors and Encourages Investors to Contact the Firm Before February 5, 2024	12-22	BU
Bellicum Pharmaceuticals : 3730 Kirby Drive, Ste. 1200 Houston, TX 77098 - Form 8-K	12-14	PU
OceanaGold Continues to Delineate High-Grade Gold Mineralization at Haile and Wharekirauponga	12-14	AQ
Canadian Natural Resources Limited Announces 2024 Budget	12-14	NE
Orrstown Financial Services, Inc. submits a non-binding term sheet to acquire Codorus Valley Bancorp, Inc. for approximately $210 million in a merger of equals transaction.	12-11	CI
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Microvast Holdings, Inc. (MVST) Investors	12-08	BU
Transcript : Washington H. Soul Pattinson and Company Limited - Shareholder/Analyst Call	12-07
Vaso Corporation entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction.	12-06	CI
Canadian Natural Resources Limited Announces 2023 Third Quarter Results	11-02	NE
OceanaGold : Q3 2023 MD&A	23-10-25	PU
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-16	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-15	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	23-10-15	GL
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023	23-10-13	CI
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)	23-10-13	BU
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa	23-10-12	PR
UCB : Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa	23-10-12	PU
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	23-10-11	GL
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	23-10-11	AQ
Severance Denied: Diag Human v Volterra Fietta [2023] EWCA Civ 1107; A Potential Public Policy Warning For Litigation Funders	23-10-11	AQ
The Legal Landscape Following The Supreme Court's Decision In PACCAR	23-10-10	AQ
UCB : to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023	23-10-09	PU
Phase 2 MIRA primary analysis trial results for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress	23-10-05	AQ
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress	23-10-04	AQ
OceanaGold Mines First Ore from Horseshoe Underground and Provides Haile Operations and Exploration Update	23-09-14	AQ
Kyodo News Digest: Aug. 31, 2023 -1-	23-08-30	AQ

No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW